Gene Therapy for ACM Due to a PKP2 Pathogenic Variant
A Phase 1/2 Study of the Safety and Efficacy of LX2020 Gene Therapy in Patients With Arrhythmogenic Cardiomyopathy Due to a Plakophilin-2 Pathogenic Variant
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Lexeo Clinical Trials
- Phone Number: 212-547-9879
- Email: clinicaltrials@lexeotx.com
Study Locations
-
-
California
-
Stanford, California, United States, 94305
- Stanford University
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Johns Hopkins University
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan
-
-
New York
-
Rochester, New York, United States, 14642
- University of Rochester
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Medical University of South Carolina
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Selected Inclusion Criteria:
- Adults with a clinical diagnosis of ACM meeting the 2010 revised Task Force Criteria (TFC)
- Genetic testing documenting a pathogenic or likely pathogenic variant in PKP2
- Frequent premature ventricular complexes (PVCs)
- Implantable cardioverter-defibrillator (ICD) implantation ≥ 12 weeks prior to the pre-screening MRI
- Left ventricular ejection fraction ≥ 40%
Selected Exclusion Criteria:
- Evidence of variant(s) in addition to PKP2 that meets the standard criteria to be considered pathogenic or likely pathogenic for ACM
- Other cardiac abnormalities as specified in the protocol
- New York Heart Association Functional Class IV at the time of consent
- History of prior gene transfer therapy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: LX2020
Single ascending dose of LX2020, with a starting dose of 2.0 x10^13 gc/kg, in multiple cohorts
|
LX2020 is an adeno-associated viral vector encoding the human Plakophilin-2 (PKP2) gene (AAVrh.10hPKP2)
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of subjects who experienced at least 1 treatment emergent adverse event (TEAE) and/or 1 treatment emergent serious adverse event (TESAE).
Time Frame: 12 months
|
Evaluation of Safety and Tolerability of LX2020
|
12 months
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Selected Exploratory
Time Frame: 12 months
|
Change in the frequency of ventricular arrhythmias from baseline.
|
12 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Lexeo Clinical Trials, Lexeo Therapeutics
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Pathologic Processes
- Heart Diseases
- Death
- Congenital Abnormalities
- Cardiovascular Abnormalities
- Heart Defects, Congenital
- Death, Sudden
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities
- Pathological Conditions, Signs and Symptoms
- Cardiomyopathies
- Heart Arrest
- Death, Sudden, Cardiac
- Arrhythmogenic Right Ventricular Dysplasia
Other Study ID Numbers
Other Study ID Numbers
- LX2020-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.